New Kisqali® data shows consistent overall survival ben

/PRNewswire/ -- Novartis today announced new Kisqali® (ribociclib) data demonstrating a consistent overall survival (OS) benefit with Kisqali plus endocrine...

Related Keywords

Norway , San Antonio , Texas , United States , New Jersey , Barcelona , Comunidad Autonoma De Cataluna , Spain , East Hanover , America , American , Julie Masow , Jamie Bennett , Sloan Simpson , Susanne Schaffert , Aleix Prat , Clin Onc , Prnewswire Novartis , American Society Of Clinical Oncology , European Society Of Medical Oncology , Twitter , Translational Research In Oncology , Novartis , Head Of The Translational Genomics Group , Novartis Pharmaceuticals , Pfizer Inc , Virtual Scientific Program , University Of Barcelona , Novartis Institutes For Biomedical Research , Astex Pharmaceuticals , Drug Administration , European Commission , Exchange Commission , Novartis Pharmaceuticals Corporation , Nj Novartis Pharmaceuticals Corporation , Akershus University Hospital , Novartis Pharmaceuticals Corp , Antonio Breast Cancer Symposium , Medical Oncology Department , Translational Genomics Group , Targeted Therapies , Solid Tumors , Clinical Oncology , Scientific Program , New England Journal , Novartis Institutes , Biomedical Research , Prescribing Information , Advanced Breast , Pharmaceuticals Corporation , European Society , Medical Oncology , Endocrine Therapy , American Society , Annual Meeting , San Antonio Breast Cancer Symposium , Biomarker Analysis , Intrinsic Subtypes , Efficacy Across , Carolina Breast Cancer , Clin Oncol , Translational Research , Evaluate Efficacy , Ribociclib With Endocrine Therapy , Adjuvant Treatment , Patients With , Breast Cancer , Health Care Amp Hospitals , Medical Pharmaceuticals , Pharmaceuticals , Clinical Trials Amp Medical Discoveries ,